Henrik Zetterberg

Research.com Recognitions

• 2026 - Research.com Medicine in Sweden Leader Award
• 2026 - Research.com Neuroscience in Sweden Leader Award
• 2025 - Research.com Best Scientists Award
• 2025 - Research.com Medicine in Sweden Leader Award
• 2025 - Research.com Neuroscience in Sweden Leader Award
• 2023 - Research.com Medicine in Sweden Leader Award
• 2022 - Research.com Medicine in Sweden Leader Award
• 2022 - Research.com Neuroscience in Sweden Leader Award

Overview

Best Publications

• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

  Kaj Blennow;Harald Hampel;Michael Weiner;Henrik Zetterberg

  2221
  Citations

• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

  Bob Olsson;Ronald Lautner;Ulf Andreasson;Annika Öhrfelt

  2170
  Citations

• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

  Oskar Hansson;Oskar Hansson;Henrik Zetterberg;Peder Buchhave;Peder Buchhave;Elisabet Londos;Elisabet Londos

  2113
  Citations

• Gut microbiome alterations in Alzheimer's disease.

  Nicholas M. Vogt;Robert L. Kerby;Kimberly A. Dill-McFarland;Sandra J. Harding

  2017
  Citations

• Defeating Alzheimer's disease and other dementias: a priority for European science and society

  Bengt Winblad;Bengt Winblad;Philippe Amouyel;Sandrine Andrieu;Clive Ballard

  1891
  Citations

• Neurofilaments as biomarkers in neurological disorders

  Michael Khalil;Charlotte E. Teunissen;Markus Otto;Fredrik Piehl

  1874
  Citations

• Clearance systems in the brain—implications for Alzheimer disease

  Jenna M. Tarasoff-Conway;Roxana O. Carare;Ricardo S. Osorio;Lidia Glodzik

  1670
  Citations

• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  Niklas Mattsson;Henrik Zetterberg;Oskar Hansson;Niels Andreasen

  1417
  Citations

• Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

  Sebastian Palmqvist;Shorena Janelidze;Yakeel T. Quiroz;Yakeel T. Quiroz;Henrik Zetterberg

  1399
  Citations

• Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.

  Thomas K. Karikari;Tharick A. Pascoal;Tharick A. Pascoal;Nicholas J. Ashton;Shorena Janelidze

  1260
  Citations

• Neurofilament light chain as a biomarker in neurological disorders

  Lorenzo Gaetani;Kaj Blennow;Paolo Calabresi;Massimiliano Di Filippo

  1213
  Citations

• Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

  Shorena Janelidze;Niklas Mattsson;Sebastian Palmqvist;Ruben Smith

  1159
  Citations

• Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

  Giulio Disanto;Christian Barro;Pascal Benkert;Yvonne Naegelin

  1154
  Citations

• A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease.

  Douglas P Wightman;Iris E Jansen;Jeanne E Savage;Alexey A Shadrin

  1034
  Citations

• Biomarkers for Alzheimer's disease: current status and prospects for the future.

  K. Blennow;H. Zetterberg

  970
  Citations

• Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

  Sebastian Palmqvist;Michael Schöll;Michael Schöll;Olof Strandberg;Niklas Mattsson

  901
  Citations

• Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.

  Charlotte E Teunissen;Inge M W Verberk;Elisabeth H Thijssen;Lisa Vermunt

  860
  Citations

• TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.

  Gernot Kleinberger;Yoshinori Yamanishi;Marc Suárez-Calvet;Eva Czirr

  856
  Citations

• Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

  Lars Lannfelt;Kaj Blennow;Henrik Zetterberg;Stellan Batsman

  850
  Citations

• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

  Harald Hampel;Richard Frank;Karl Broich;Stefan J. Teipel

  803
  Citations

• The Neuropathology and Neurobiology of Traumatic Brain Injury

  Kaj Blennow;John Hardy;Henrik Zetterberg;Henrik Zetterberg

  749
  Citations

• Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.

  Peder Buchhave;Lennart Minthon;Henrik Zetterberg;Åsa K. Wallin

  720
  Citations